WO2023111544A3 - Benzoate salt of 5-methoxy-n,n-dimethyltryptamine - Google Patents

Benzoate salt of 5-methoxy-n,n-dimethyltryptamine Download PDF

Info

Publication number
WO2023111544A3
WO2023111544A3 PCT/GB2022/053208 GB2022053208W WO2023111544A3 WO 2023111544 A3 WO2023111544 A3 WO 2023111544A3 GB 2022053208 W GB2022053208 W GB 2022053208W WO 2023111544 A3 WO2023111544 A3 WO 2023111544A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyltryptamine
methoxy
benzoate salt
salt
dmt
Prior art date
Application number
PCT/GB2022/053208
Other languages
French (fr)
Other versions
WO2023111544A2 (en
Inventor
Cosmo FEILDING-MELLEN
Jason Gray
Timothy Mason
Cosima Agnes RUDD GRETTON
Frank Wiegand
Original Assignee
Beckley Psytech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2118008.8A external-priority patent/GB202118008D0/en
Priority claimed from GBGB2118005.4A external-priority patent/GB202118005D0/en
Priority claimed from GBGB2118006.2A external-priority patent/GB202118006D0/en
Priority claimed from GBGB2118007.0A external-priority patent/GB202118007D0/en
Priority claimed from GBGB2118011.2A external-priority patent/GB202118011D0/en
Priority claimed from GBGB2118099.7A external-priority patent/GB202118099D0/en
Priority claimed from GBGB2118095.5A external-priority patent/GB202118095D0/en
Priority claimed from GBGB2118156.5A external-priority patent/GB202118156D0/en
Priority claimed from GBGB2212117.2A external-priority patent/GB202212117D0/en
Priority claimed from GBGB2212113.1A external-priority patent/GB202212113D0/en
Priority to CA3242602A priority Critical patent/CA3242602A1/en
Application filed by Beckley Psytech Limited filed Critical Beckley Psytech Limited
Priority to AU2022413759A priority patent/AU2022413759A1/en
Publication of WO2023111544A2 publication Critical patent/WO2023111544A2/en
Publication of WO2023111544A3 publication Critical patent/WO2023111544A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.
PCT/GB2022/053208 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine WO2023111544A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3242602A CA3242602A1 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
AU2022413759A AU2022413759A1 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
GBGB2118005.4A GB202118005D0 (en) 2021-12-13 2021-12-13 Methods of synthesis
GBGB2118007.0A GB202118007D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GBGB2118006.2A GB202118006D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GB2118011.2 2021-12-13
GB2118006.2 2021-12-13
GBGB2118011.2A GB202118011D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GB2118007.0 2021-12-13
GB2118008.8 2021-12-13
GB2118005.4 2021-12-13
GBGB2118008.8A GB202118008D0 (en) 2021-12-13 2021-12-13 Combination Pharmaceutical composition
GBGB2118099.7A GB202118099D0 (en) 2021-12-14 2021-12-14 Methods of synthesis
GB2118099.7 2021-12-14
GBGB2118095.5A GB202118095D0 (en) 2021-12-14 2021-12-14 Combination pharmaceutical composition
GB2118095.5 2021-12-14
GB2118156.5 2021-12-15
GBGB2118156.5A GB202118156D0 (en) 2021-12-15 2021-12-15 Methods of synthesis
GB202118309 2021-12-16
GB2118295.1 2021-12-16
GB2118309.0 2021-12-16
GB2118293.6 2021-12-16
GB2118305.8 2021-12-16
GB202118293 2021-12-16
GB202118305 2021-12-16
GB202118295 2021-12-16
GBGB2212117.2A GB202212117D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GBGB2212113.1A GB202212113D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GB2212117.2 2022-08-19
GB2212113.1 2022-08-19

Publications (2)

Publication Number Publication Date
WO2023111544A2 WO2023111544A2 (en) 2023-06-22
WO2023111544A3 true WO2023111544A3 (en) 2023-07-20

Family

ID=84627509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/053208 WO2023111544A2 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Country Status (3)

Country Link
AU (1) AU2022413759A1 (en)
CA (1) CA3242602A1 (en)
WO (1) WO2023111544A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186798A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-meo-dmt for use in the treatment of sleep disturbance
US20240101514A1 (en) * 2022-08-19 2024-03-28 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024105379A1 (en) * 2022-11-14 2024-05-23 Beckley Psytech Limited Formulations of 5-meo-dmt

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021222885A1 (en) * 2020-05-01 2021-11-04 Zosano Pharma Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021250435A1 (en) * 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021222885A1 (en) * 2020-05-01 2021-11-04 Zosano Pharma Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021250435A1 (en) * 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FALKENBERG G., CARLSTRÖM D.: "The crystal and molecular structure of 5-methoxy-(N,N)-dimethyltryptamine hydrochloride", ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY., MUNKSGAARD, COPENHAGEN., DK, vol. 27, no. 2, 15 February 1971 (1971-02-15), DK, pages 411 - 418, XP009529821, DOI: 10.1107/S0567740871002309 *

Also Published As

Publication number Publication date
CA3242602A1 (en) 2023-06-22
WO2023111544A2 (en) 2023-06-22
AU2022413759A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
WO2023111544A3 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
MX2022001421A (en) Tetracyclic compound, preparation method therefor and use thereof.
MX2023003778A (en) Antitumor compound, and preparation method therefor and use thereof.
JOP20190042A1 (en) Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator
CY1118189T1 (en) ENLARGEMENT OF SALT WATER AND GLUT WATER BY ADMINISTRATION OF A SOIL CALCIUM SOLUTION IN SOFT WATER
EP4293104A3 (en) Cell-free production of ribonucleic acid
MX2022015562A (en) Phthalazinone compound, and preparation method therefor and medical use thereof.
MX336191B (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application.
EA201490269A1 (en) NEW DERIVATIVE 1,2,3,4-TETRAHYDROCHINOLINE SUITABLE FOR TREATMENT OF DIABETES
EA201290416A1 (en) NEW SPYROPYPERIDINE CONNECTIONS
EA202193015A1 (en) CDK INHIBITORS
WO2014047662A3 (en) Indazole derivatives and uses thereof
MX342746B (en) Nitrogen mustard derivatives.
MX2019004845A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors.
EP4031529C0 (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2020008678A (en) Methods of use for trisubstituted benzotriazole derivatives.
MX2022003504A (en) Irak inhibitor and preparation method therefor and use thereof.
PH12019550154A1 (en) Azetidine derivative
MX2023009037A (en) Pyrimidopyran compound.
MX2019014470A (en) Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of derivative thereof and method for preparing same.
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
EA201492104A1 (en) Inhibitor JAK1 / 2
CO6341557A2 (en) NITROGEN DERIVATIVES OF PANCRATISTATINE
CY1123916T1 (en) A COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND CAPABLE OF INCREASING THE LEVEL OF H2O2 IN CANCER CELLS OF A SUBJECT
MX2022004579A (en) Thiophene derivatives for use in treating portal inflammation and fibrosis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22830588

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 811798

Country of ref document: NZ

Ref document number: AU2022413759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3242602

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022413759

Country of ref document: AU

Date of ref document: 20221213

Kind code of ref document: A